This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.

Why Toyota's Move to Fuel Cells Won't Affect Electric Vehicle Sales

Toyota is scrapping its electric vehicle line to go into fuel cells. Is this a step backwards? Not really.

Why Vertex Pharmaceuticals Will Likely Climb to New High

Vertex Pharmaceuticals is now within weeks, or even days, of announcing top-line results on its two phase 3 cystic fibrosis studies. The science, phase 2 data, and FDA approval history for cystic fibrosis all suggest that Vertex is about to explode higher.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs